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ABSTRACT : Carcinoma-containing CEA was measured as compared with nor-
mal tissues and metastases in the lymph nodes and the liver. 
     The high CEA production was remarkable in the potent malignant tumors and 
metastases in the liver and the lymph nodes as compared with those in normal colon 
tissues as well as in non metastatic lymph nodes. 
     It is reasonable to consider that high plasma CEA may well indicate advanc-
ing or highly potent malignant diseases or recurrence of colon cancers due to 
destruction of vascular structure by cancer invasion.
       INTRODUCTION 
 The measurement of carcinoembryonic anti-
gen (CEA) in serum has been of use to clini-
cally detect a presence of colon cancer and its 
recurrence. An extraordinarily clinical preva-
lance in use has been achieved, but the mecha-
nism of CEA production and transmission to 
the serum is not clear yet. 
 This study is to clarify the mechanism as to 
where CEA is produced and how it is transmit-
ted to the serum by means of measuring the 
tissue CEA in cancer mass and the surrounding 
tissues independently. 
    METERIAL AND METHOD 
 Fifty-seven cases surgically treated for colon 
cancers were eligible for this study. According 
to the location of colon cancers, 14 were in
right half the colon, 19 in the left half and 24 
in the rectum respectively. 
 According to the histologic type, 1 1 were 
well differentiated adenocarcinoma, 39 moder-
ate, four undifferentiated and three mutinous 
respectively. 
 These included three with liver metastases, 
and the dissected lymph nodes were subjected 
to this study. There were 16 metastatic nodes 
and 24 normal one. Tissue-containing CEA were 
measured by using the surgical specimens and 
dissected nodes. These were cut into pieces of 
as large as 0. 5 to 1g in 3- 5ml cold normal 
saline per gram of tissue and homogenized at 
4°C in phosphate buffer saline of pH 7.2-7.4 
with ultrafurrox homogenizer (HITACHI 2 0 
PR-52D). After centrifugation at 1600g for 20 
min, the supernatant was tested by the micro 
immuno-assay method. Tissue CEA was cal-
culated by ng/tissue weight (g). 
 In this study the surgical specimens were tak-
en from apparently proliferating part of the 
tumor mass near the margin of the tumor, avoi-
ding to take the necrotic site in the middle of 
the tumor mass. Parts of the tissue, 3 cm 
proximal and distal to the visible tumor mar-
gin, were taken to compare with the tumor 
mass. 
          RESULT 
 Tissue CEA was compared in accordance 
with the location of the tumor as shown in Fig. 
1.
well : well differentiated adenocarcinoma 
mod.: moderately, undiff. : undifferentiated 
muci : mutinous 
Fig. 2. Relationship between tissue-containing 
      CEA and histologic patterns of differen-
      tiation.
Fig. 1. Relationship between tissue-containing 
      CEA and the location of colon cancer. 
 There was no specific pattern concerning the 
tumor location, although tissue CEA of can-
cers originated from the right half of the colon 
showed somewhat low. 
 According to histologic diferentiation, tissue 
CEA in undifferentiated adenocarcinoma were 
lower rather than those in well and moderate 
adenocarcinomas as shown in Fig. 2.
 Furthermore, that in mutinous carcinoma 
showed the lowest. It is a reflection that 
tissue-CEA is decreasing in accordance with 
the potent clinical malignancy. CEA in the 
tissues 3 cm distant from the tumor mass 
showed significantly lower than those in the 
tumor. However, there was no significant dif-
ference between the tissues 3 cm proximal and 
distal to the tumor in spite of presenting the 
lower CEA of the normal lymph nodes tissues. 
 Fig.3 indicates high CEA of the metastatic 
lymph nodes as compared with the non-meta-
static one. It was almost the same as those of 
the tumor massess. Tissue CEA of the meta-
static tumor into the liver had become higher 
than that of the metastatic lymph node. 
 It was evident that metastatic foci were con-
taining and producing large amount of CEA.
Fig. 3. Tissue-containing CEA in each site
         DISCUSSION 
 The measurement of CEA in colon cancer is 
of benefit to diagnose and/or treat in clinical 
use.1) 2) 3) 
 It is well known that CEA is produced by 
cancer cells and transmitted to the portal ves-
sel. However, the mechanism of an increase in 
CEA is not clearly understood, for example, 
1)capacity of CEA productions) 2) 2 )transmis-
sion to the vessel and its speed 3)-5) 3)metabo-
lism of CEA in the lung and the liver6) 7) and 
4 )absorption of it from the intestinal epi-
thelium. 
 The factors contributing to an increase in 
CEA are as follows, histologic types, depth of 
cancer invasion, vascular invasion, distant 
metastasis, staging classification by Dukes and 
so on.3)-5) Of interest is the fact that a pres-
ence of vascular invasion is the most increa-
sing factor. Bivvs 3) also reported that an in-
crease in plasma CEA is mostly influenced by 
vascular invasion. 
 In this present study, it is worthwhile to em-
phasize that the more the potent malignancy 
of the tumor, the higher CEA in the tumor re-
mains. It is suggested that higher malignant
tumors including metastases in the lymph 
nodes and the liver have high activities of CEA 
production. 
  In fact, plasma CEA is not necessarily pro-
portional to CEA production in the tumors. 
Pvr-r 8 )commented on this possibility that as 
soon as plasma CEA is derived from the tumor, 
it responds potentially to CEA antibody in 
plasma and changes into immunocomplex that 
makes CEA inactive. 
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